Targeted Oncology6d
Novel ADC Shows Promise of Targeting CD46 in mCRPC
The antibody-drug conjugate FOR46 showed the strong potential of using CD46 as a new therapeutic target in metastatic ...
FibroGen announces publication of results from Phase 1 study of FG-3246
FibroGen (FGEN) announced the peer-reviewed publication titled “A Phase 1, First-in-Human Study of FOR46, an Immune-Modulating Antibody-Drug ...
FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference
SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending the 24th Annual Needham Virtual Healthcare Conference taking place ...
FibroGen Down on Peer-Review Publication
FibroGen, Inc. (NASDAQ: FGEN) today announced the peer-reviewed publication titled “A Phase 1, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in ...
FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results
Detailed price information for Fibrogen Inc CS (FGEN-Q) from The Globe and Mail including charting and trades.
FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients [...]
(NASDAQ: FGEN) today announced the peer-reviewed publication titled “A Phase 1, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients with ...